Cargando…
Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
PURPOSE: To investigate the prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma (ESCC) treated with definitive (chemo)radiotherapy. METHODS: A total of 98 ESCC patients with cTNM stage T1-4, N1-3, M0 who received definitive (chemo)radiotherapy after (18)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960216/ https://www.ncbi.nlm.nih.gov/pubmed/36829219 http://dx.doi.org/10.1186/s13014-023-02224-5 |
_version_ | 1784895461041111040 |
---|---|
author | Xia, Lianshuang Li, Xiaoxu Zhu, Jie Gao, Zhaisong Zhang, Ju Yang, Guangjie Wang, Zhenguang |
author_facet | Xia, Lianshuang Li, Xiaoxu Zhu, Jie Gao, Zhaisong Zhang, Ju Yang, Guangjie Wang, Zhenguang |
author_sort | Xia, Lianshuang |
collection | PubMed |
description | PURPOSE: To investigate the prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma (ESCC) treated with definitive (chemo)radiotherapy. METHODS: A total of 98 ESCC patients with cTNM stage T1-4, N1-3, M0 who received definitive (chemo)radiotherapy after (18)F-FDG PET/CT examination from December 2013 to December 2020 were retrospectively analyzed. Clinical factors included age, sex, histologic differentiation grade, tumor location, clinical stage, and treatment strategies. Parameters obtained by (18)F-FDG PET/CT included SUV(max) of primary tumor (SUV(Tumor)), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUV(max) of lymph node (SUV(LN)), PET positive lymph nodes (PLNS) number, the shortest distance between the farthest PET positive lymph node and the primary tumor in three-dimensional space after the standardization of the patient BSA (SD(max(LN-T))). Univariate and multivariate analysis was conducted by Cox proportional hazard model to explore the significant factors affecting overall survival (OS) and progression-free survival (PFS) in ESCC patients. RESULTS: Univariate analysis showed that tumor location, SUV(Tumor), MTV, TLG, PLNS number, SD(max (LN-T)) were significant predictors of OS and tumor location, and clinical T stage, SUV(Tumor), MTV, TLG, SD(max (LN-T)) were significant predictors of PFS (all p < 0.1). Multivariate analysis showed that MTV and SD(max (LN-T)) were independent prognostic factors for OS (HR = 1.018, 95% CI 1.006–1.031; p = 0.005; HR = 6.988, 95% CI 2.119–23.042; p = 0.001) and PFS (HR = 1.019, 95% CI 1.005–1.034; p = 0.009; HR = 5.819, 95% CI 1.921–17.628; p = 0.002). Combined with independent prognostic factors MTV and SD(max (LN-T)), we can further stratify patient risk. CONCLUSIONS: Before treatment, (18)F-FDG PET/CT has important prognostic value for patients with ESCC treated with definitive (chemo)radiotherapy. The lower the value of MTV and SD(max (LN-T)), the better the prognosis of patients. |
format | Online Article Text |
id | pubmed-9960216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99602162023-02-26 Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy Xia, Lianshuang Li, Xiaoxu Zhu, Jie Gao, Zhaisong Zhang, Ju Yang, Guangjie Wang, Zhenguang Radiat Oncol Research PURPOSE: To investigate the prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma (ESCC) treated with definitive (chemo)radiotherapy. METHODS: A total of 98 ESCC patients with cTNM stage T1-4, N1-3, M0 who received definitive (chemo)radiotherapy after (18)F-FDG PET/CT examination from December 2013 to December 2020 were retrospectively analyzed. Clinical factors included age, sex, histologic differentiation grade, tumor location, clinical stage, and treatment strategies. Parameters obtained by (18)F-FDG PET/CT included SUV(max) of primary tumor (SUV(Tumor)), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUV(max) of lymph node (SUV(LN)), PET positive lymph nodes (PLNS) number, the shortest distance between the farthest PET positive lymph node and the primary tumor in three-dimensional space after the standardization of the patient BSA (SD(max(LN-T))). Univariate and multivariate analysis was conducted by Cox proportional hazard model to explore the significant factors affecting overall survival (OS) and progression-free survival (PFS) in ESCC patients. RESULTS: Univariate analysis showed that tumor location, SUV(Tumor), MTV, TLG, PLNS number, SD(max (LN-T)) were significant predictors of OS and tumor location, and clinical T stage, SUV(Tumor), MTV, TLG, SD(max (LN-T)) were significant predictors of PFS (all p < 0.1). Multivariate analysis showed that MTV and SD(max (LN-T)) were independent prognostic factors for OS (HR = 1.018, 95% CI 1.006–1.031; p = 0.005; HR = 6.988, 95% CI 2.119–23.042; p = 0.001) and PFS (HR = 1.019, 95% CI 1.005–1.034; p = 0.009; HR = 5.819, 95% CI 1.921–17.628; p = 0.002). Combined with independent prognostic factors MTV and SD(max (LN-T)), we can further stratify patient risk. CONCLUSIONS: Before treatment, (18)F-FDG PET/CT has important prognostic value for patients with ESCC treated with definitive (chemo)radiotherapy. The lower the value of MTV and SD(max (LN-T)), the better the prognosis of patients. BioMed Central 2023-02-24 /pmc/articles/PMC9960216/ /pubmed/36829219 http://dx.doi.org/10.1186/s13014-023-02224-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xia, Lianshuang Li, Xiaoxu Zhu, Jie Gao, Zhaisong Zhang, Ju Yang, Guangjie Wang, Zhenguang Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title | Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title_full | Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title_fullStr | Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title_full_unstemmed | Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title_short | Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
title_sort | prognostic value of baseline (18)f-fdg pet/ct in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960216/ https://www.ncbi.nlm.nih.gov/pubmed/36829219 http://dx.doi.org/10.1186/s13014-023-02224-5 |
work_keys_str_mv | AT xialianshuang prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT lixiaoxu prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT zhujie prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT gaozhaisong prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT zhangju prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT yangguangjie prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy AT wangzhenguang prognosticvalueofbaseline18ffdgpetctinpatientswithesophagealsquamouscellcarcinomatreatedwithdefinitivechemoradiotherapy |